// App-Quantinova.ai

POS0907 (2021) : EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

Researchers

Presenter

  • A. Deodhar

Principal Investigators

  • X. Baraliakos

  • I. Mcinnes

  • K. De Vlam

  • L. Bessette

  • A. Maniccia

  • R. Lippe

  • C. Saffore

  • T. Gao

  • I. H. Song

  • A. Ostor

Medical Centers

  • Oregon Health & Science University, Portland, United States of America

  • Ruhr-University-Bochum, Radiology, Bochum, Germany

  • University of Glasgow, Glasgow, United Kingdom

  • University Hospitals Leuven, Ophthalmology, Leuven, Belgium

  • Laval University, Rheumatology, Québec City, Canada

  • AbbVie Deutschland GmbH & Co. KG, Immunology, Berlin, Germany

  • Cabrini Hospital, Monash University & Emeritus Research Melbourne, Melbourne, Australia

Locations

  • United States

  • Germany

  • United Kingdom

  • Belgium

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Nutritional risk screening

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II/III

Study Id's

  • NCT03178487

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved